New possibilities of predicting the outcomes of antiviral therapy in patients with chronic hepatitis B

Objective. To develop a procedure for predicting the outcomes of antiviral therapy with entecavir in HBeAg-negative patients with chronic hepatitis B (CHB). Subjects and methods. A total of 154 primary patients with HBeAg-negative CHB were examined. The diagnosis was made on the basis of clinical, epidemiological, biochemical, instrumental, serological, and molecular genetic studies. The findings were subjected to mathematical and statistical processing that included descriptive assessment, discriminant analysis, and distribution normality analysis using the x2 test and the Kolmogorov-Smirnov goodness-of-fit test. Conclusion. A discriminant model has been developed, which can predict the outcome of antiviral therapy with entecavir in patients with HBeAg-negative CHB before treatment, with the probability of an erroneous prognosis of less than 10-26, which is recommended to be used in clinical practice to treat this category of patients.

chronic viral hepatitis B, entecavir, antiviral therapy, prognosis